Akorn (AKRX) Reports Wider Q2 Loss
More News related to AKRX
- Akorn (AKRX) Posts Q3 Loss of $0.06, Beats By 2c
- Akorn Reports Third Quarter 2009 Financial Results; Launches Two New Products: Ketorolac Tromethamine Ophthalmic and Hydralazine HCL
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
- Akorn (AKRX) Files Shelf Offering of Up To 13.3M Shares
More News related to Earnings
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
Akorn, Inc. (NASDAQ: AKRX) reports Q2 loss of $0.08, compared to a loss of $0.03 in the same quarter last year. Revenue for the quarter was $16.3 million, versus $21.2 million in the same quarter last year.
Related Categories
EarningsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
